| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ioannis Mantas, Yunting Yang, Clotilde Mannoury-la-Cour, Mark J Millan, Xiaoqun Zhang, Per Svenningsso. Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia. Neuropharmacology. vol 162. 2021-01-06. PMID:31666199. |
parkinson's disease (pd) is characterized by progressive loss of midbrain dopaminergic neurons and treated with the dopamine precursor, 3,4-dihydroxy-l-phenylalanine (l-dopa). |
2021-01-06 |
2023-08-13 |
mouse |
| A J Robison, Katharine N Thakkar, Vaibhav A Diwadka. Cognition and Reward Circuits in Schizophrenia: Synergistic, Not Separate. Biological psychiatry. vol 87. issue 3. 2021-01-06. PMID:31733788. |
we then expand on the role of glutamatergic inputs to these dopamine circuits and dopaminergic modulation of critical excitatory pathways with attention given to the role of glutamatergic hippocampal outputs onto nucleus accumbens. |
2021-01-06 |
2023-08-13 |
human |
| Yu-Chia Chen, Diego Baronio, Svetlana Semenova, Shamsiiat Abdurakhmanova, Pertti Panul. Cerebral Dopamine Neurotrophic Factor Regulates Multiple Neuronal Subtypes and Behavior. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 40. issue 32. 2021-01-04. PMID:32631936. |
cerebral dopamine neurotrophic factor (cdnf) protects dopaminergic neurons against toxic damage in the rodent brain and is in clinical trials to treat parkinson's disease patients. |
2021-01-04 |
2023-08-13 |
zebrafish |
| Fillipe M de Araújo, Lorena Cuenca-Bermejo, Emiliano Fernández-Villalba, Silvia L Costa, Victor Diogenes A Silva, Maria Trinidad Herrer. Role of Microgliosis and NLRP3 Inflammasome in Parkinson's Disease Pathogenesis and Therapy. Cellular and molecular neurobiology. 2021-01-02. PMID:33387119. |
parkinson's disease (pd) is a neurodegenerative disorder marked primarily by motor symptoms such as rigidity, bradykinesia, postural instability and resting tremor associated with dopaminergic neuronal loss in the substantia nigra pars compacta (snpc) and deficit of dopamine in the basal ganglia. |
2021-01-02 |
2023-08-13 |
Not clear |
| Michael Silkstone, Stefan M Brudzynsk. Dissimilar interaction between dopaminergic and cholinergic systems in the initiation of emission of 50-kHz and 22-kHz vocalizations. Pharmacology, biochemistry, and behavior. vol 188. 2020-12-31. PMID:31655084. |
emission of 50-khz usvs is dependent upon the activation of dopaminergic neurons located within the ventral tegmental area that release dopamine into the medial shell of the nucleus accumbens. |
2020-12-31 |
2023-08-13 |
rat |
| Nikita Katila, Sunil Bhurtel, Pil-Hoon Park, Jin Tae Hong, Dong-Young Cho. Activation of AMPK/aPKCζ/CREB pathway by metformin is associated with upregulation of GDNF and dopamine. Biochemical pharmacology. vol 180. 2020-12-31. PMID:32800853. |
parkinson's disease (pd) is the second most common neurodegenerative disease, which is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, leading to a decrease in striatal dopamine. |
2020-12-31 |
2023-08-13 |
mouse |
| Ali Gheidi, Lora M Cope, Christopher J Fitzpatrick, Benjamin N Froehlich, Rachel Atkinson, Coltrane K Groves, Clair N Barcelo, Jonathan D Morro. Effects of the cannabinoid receptor agonist CP-55,940 on incentive salience attribution. Psychopharmacology. vol 237. issue 9. 2020-12-30. PMID:32494975. |
recent evidence has shown that activity of the endocannabinoid system increases dopaminergic activity in the mesocorticolimbic system, and other studies have shown that sign-tracking behaviors are dependent on dopamine. |
2020-12-30 |
2023-08-13 |
Not clear |
| Daniel S Drew, Kinan Muhammed, Fahd Baig, Mark Kelly, Youssuf Saleh, Nagaraja Sarangmat, David Okai, Michele Hu, Sanjay Manohar, Masud Husai. Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder. Brain : a journal of neurology. vol 143. issue 8. 2020-12-30. PMID:32761061. |
being off dopaminergic medication overnight did not modulate pupillary reward sensitivity in impulse control disorder patients, whereas in control patients reward sensitivity was significantly reduced when off dopamine. |
2020-12-30 |
2023-08-13 |
human |
| Daniel S Drew, Kinan Muhammed, Fahd Baig, Mark Kelly, Youssuf Saleh, Nagaraja Sarangmat, David Okai, Michele Hu, Sanjay Manohar, Masud Husai. Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder. Brain : a journal of neurology. vol 143. issue 8. 2020-12-30. PMID:32761061. |
however, there was no difference in reward sensitivity between patient groups when on dopamine medication, suggesting that impulse control disorders may not emerge simply because of a direct effect of dopaminergic drug level on reward sensitivity. |
2020-12-30 |
2023-08-13 |
human |
| Mariana de Souza Aranha Garcia-Gomes, Dennis Albert Zanatto, Orfa Yineth Galvis-Alonso, Jorge Mejia, Ana Tada Fonseca Brasil Antiorio, Pedro Kenzo Yamamoto, Márcia Carolina Millán Olivato, Thaísa Meira Sandini, Jorge Camilo Flório, Ivo Lebrun, Silvia Maria Gomes Massironi, Sandra Regina Alexandre-Ribeiro, Maria Martha Bernardi, Susan Ienne, Tiago Antonio de Souza, Maria Lúcia Zaidan Dagli, Claudia Madalena Cabrera Mor. Behavioral and neurochemical characterization of the spontaneous mutation tremor, a new mouse model of audiogenic seizures. Epilepsy & behavior : E&B. vol 105. 2020-12-29. PMID:32109856. |
regarding to dopaminergic system, neither dopamine (da) and 3,4-dihydroxyphenylacetic acid (dopac) contents nor the turnover rate of da showed statistically significant differences between wt and mutant mice. |
2020-12-29 |
2023-08-13 |
mouse |
| Timothy G Freels, Daniel B K Gabriel, Deranda B Lester, Nicholas W Simo. Risky decision-making predicts dopamine release dynamics in nucleus accumbens shell. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 45. issue 2. 2020-12-28. PMID:31546248. |
it is well-established that dopaminergic drugs modulate risk-taking; however, little is known about how differences in baseline phasic dopamine signaling drive individual differences in risk preference. |
2020-12-28 |
2023-08-13 |
human |
| Min Lin, Luis M Colon-Perez, Danielle O Sambo, Douglas R Miller, Joseph J Lebowitz, Felix Jimenez-Rondan, Robert J Cousins, Nicole Horenstein, Tolunay Beker Aydemir, Marcelo Febo, Habibeh Khoshboue. Mechanism of Manganese Dysregulation of Dopamine Neuronal Activity. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 40. issue 30. 2020-12-25. PMID:32576620. |
it is unknown, however, how manganese accumulates in dopaminergic brain regions or how it regulates the activity of dopamine neurons. |
2020-12-25 |
2023-08-13 |
Not clear |
| Qi Mao, Wang-Zhi Qin, Ao Zhang, Na Y. Recent advances in dopaminergic strategies for the treatment of Parkinson's disease. Acta pharmacologica Sinica. vol 41. issue 4. 2020-12-21. PMID:32112042. |
based on the loss of dopamine or dopaminergic dysfunction in pd patients, most of the current therapies focus on symptomatic relief to improve patient quality of life. |
2020-12-21 |
2023-08-13 |
Not clear |
| Qi Mao, Wang-Zhi Qin, Ao Zhang, Na Y. Recent advances in dopaminergic strategies for the treatment of Parkinson's disease. Acta pharmacologica Sinica. vol 41. issue 4. 2020-12-21. PMID:32112042. |
as dopamine replacement treatment remains the most effective symptomatic pharmacotherapy for pd, herein we provide an overview of the current pharmacotherapies, summarize the clinical development status of novel dopaminergic agents, and highlight the challenge and opportunity of emerging preclinical dopaminergic approaches aimed at managing the features and progression of pd. |
2020-12-21 |
2023-08-13 |
Not clear |
| Changliang Li. Targeting the cholinergic system in Parkinson's disease. Acta pharmacologica Sinica. vol 41. issue 4. 2020-12-21. PMID:32132659. |
in addition to dopaminergic innervation, giant aspiny cholinergic interneurons (chis) within the striatum have long been recognized as a critical node for balancing dopamine signaling and regulating movement. |
2020-12-21 |
2023-08-13 |
Not clear |
| Serda Kecel-Gunduz, Yasemin Budama-Kilinc, Rabia Cakir-Koc, Tolga Zorlu, Bilge Bicak, Yagmur Kokcu, Zeynep Kaya, Aysen E Ozel, Sevim Akyu. In silico Analysis of Sulpiride, Synthesis, Characterization and In vitro Studies of its Nanoparticle for the Treatment of Schizophrenia. Current computer-aided drug design. vol 16. issue 2. 2020-12-17. PMID:31244443. |
sulpiride, which has selective dopaminergic blocking activity, is a substituted benzamide antipsychotic drug playing a prominent role in the treatment of schizophrenia, which more selective and primarily blocks dopamine d2 and d3 receptor. |
2020-12-17 |
2023-08-13 |
Not clear |
| Matthieu Béreau, Paul Krack, Norbert Brüggemann, Thomas F Münt. Neurobiology and clinical features of impulse control failure in Parkinson's disease. Neurological research and practice. vol 1. 2020-12-17. PMID:33324875. |
they result from sensitization of the mesocorticolimbic pathway that arose in predisposed pd patients concomitantly with spreading of pd pathology, non-physiological dopaminergic and pulsatile administration of dopamine replacement therapy (drt). |
2020-12-17 |
2023-08-13 |
Not clear |
| Chao-Qun Lin, Lu-Kui Che. Cerebral dopamine neurotrophic factor promotes the proliferation and differentiation of neural stem cells in hypoxic environments. Neural regeneration research. vol 15. issue 11. 2020-12-11. PMID:32394962. |
previous research found that cerebral dopamine neurotrophic factor (cdnf) has a protective effect on brain dopaminergic neurons, and cdnf is regarded as a promising therapeutic agent for neurodegenerative diseases. |
2020-12-11 |
2023-08-13 |
rat |
| Christine Bus, Laimdota Zizmare, Marita Feldkaemper, Sven Geisler, Maria Zarani, Anna Schaedler, Franziska Klose, Jakob Admard, Craig J Mageean, Giuseppe Arena, Petra Fallier-Becker, Aslihan Ugun-Klusek, Klaudia K Maruszczak, Konstantina Kapolou, Benjamin Schmid, Doron Rapaport, Marius Ueffing, Nicolas Casadei, Rejko Krüger, Thomas Gasser, Daniela M Vogt Weisenhorn, Philipp J Kahle, Christoph Trautwein, Christian J Gloeckner, Julia C Fitzgeral. Human Dopaminergic Neurons Lacking PINK1 Exhibit Disrupted Dopamine Metabolism Related to Vitamin B6 Co-Factors. iScience. vol 23. issue 12. 2020-12-11. PMID:33299968. |
human dopaminergic neurons lacking pink1 exhibit disrupted dopamine metabolism related to vitamin b6 co-factors. |
2020-12-11 |
2023-08-13 |
human |
| Seunghyi Kook, Xuanzhi Zhan, Kimberly Thibeault, Mohamed R Ahmed, Vsevolod V Gurevich, Eugenia V Gurevic. Mdm2 enhances ligase activity of parkin and facilitates mitophagy. Scientific reports. vol 10. issue 1. 2020-12-10. PMID:32193420. |
loss-of-function mutations in the e3 ubiquitin ligase parkin have been implicated in the death of dopaminergic neurons in the substantia nigra, which is the root cause of dopamine deficit in the striatum in parkinson's disease. |
2020-12-10 |
2023-08-13 |
Not clear |